Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.

Article Details

Citation

Narayanan S, Kunz PL

Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.

Hematol Oncol Clin North Am. 2016 Feb;30(1):163-77. doi: 10.1016/j.hoc.2015.09.008.

PubMed ID
26614375 [ View in PubMed
]
Abstract

Neuroendocrine tumors (NETs) are rare epithelial neoplasms with neuroendocrine differentiation originating most commonly in the lungs and gastroenteropancreatic. Treatment includes surgery and other local therapies; treatment of inoperable disease centers around symptom management and control of tumor growth. Somatostatin analogues (SSAs) have been a mainstay of managing hormone-related symptoms. Emerging evidence suggests that they are effective therapies for tumor control also. Peptide receptor radionuclide therapy with radiolabeled SSAs is a new, promising treatment for inoperable or metastatic NETs. This article reviews the role of SSAs in the treatment of NETs.

DrugBank Data that Cites this Article

Drugs